(CNN) – The COVID-19 vaccines created at least nine new billionaires after stocks in the companies that produce the doses soared.
At the top of the list of new billionaires are Stephane Bancel, CEO of Moderna and Ugur Sahin, CEO of BioNTech, which produced one of the vaccines together with Pfizer. Both CEOs now have a wealth of about US$ 4.000 millones, according to an analysis of People’s Vaccine Alliance, a group that includes Oxfam, UNAIDS, Global Justice Now and Amnesty International.
Senior executives at Chinese company CanSino Biologics and Moderna’s early investors also became billionaires on paper as stocks soared, partly in anticipation of the benefits to be made from covid-19 vaccines. that also augur good prospects for the future for companies. The analysis was compiled using data from the Forbes millionaires list.
Read also: Mercado improved its growth projections for the country: Most optimistic actor points to 9%
The meteoric rise of the shares of Moderna, BioNTech and CanSino
Moderna’s share price increased more than 700% from February 2020. BioNTech’s, meanwhile, shot up 600%. CanSino Biologics stock increased approximately 440% during the same period. The company’s single-dose vaccine was approved for use in China in February.
Activists said that wealth generation underscores the stark inequality that emerges as a result of the pandemic. The new nine billionaires have a combined wealth of US $ 19.3 trillion, enough money to fully vaccinate some 780 million people in low-income countries, according to activists.
These billionaires are the human face of the huge profits that many monopoly pharmaceutical corporations they have about these vaccines, ”Anne Marriott, Oxfam’s head of health policy, said in a statement. These vaccines were financed with public money and should be first and foremost a global public good, not a private profit opportunity, “he added.
Read also: Gianfranco Battisti, CEO of the FS Group: “Italy has returned to compete in high-speed trains”
The discussion about vaccine patents
The report matches the G20 Global Health Summit which takes place this Friday, in which world leaders discuss the possibility of waiving intellectual property rights on vaccines.
The president of United States, Joe Biden, backed the move that supporters say will help expand global supply and reduce the vaccination gap between rich and poor countries. Opponents like Germany have argued that protecting intellectual property is vital for innovation, saying that removing patents will not significantly increase supply due to limited production capacity and insufficient number of vaccine components.
According to the World Health Organization (WHO), the 87% of vaccine doses have gone to high-income countries or upper mids. Low-income countries, for their part, have received only 0.2%. In a document released Friday, IMF chief economist Gita Gopinath said that vaccinating 60% of the world’s population by mid-2022 would cost just $ 50 billion.
Read also: Fintech industry: An engine in financial inclusion and digital transformation
Albert Bourla, CEO of Pfizer, said during Friday’s summit that the company provide 2 billion doses of its vaccine to low-income countries and media for the next 18 months. Pfizer expects its vaccine sales to total $ 26 billion by the end of this year, with a profit margin close to 30%.
Bourla defended the decision to profit from the vaccine. He indicated that his company assumed all the risk to develop it and invested $ 2 billion in research and development.
Obstacles to supply
BioNTech, which received 325 million euros (US $ 397 million) from the German government to develop the vaccine, said it is committed to supplying it to low-income countries at cost.. “We all know that no one is going to be safe until everyone is safe”the company added.
Among the greatest obstacles to increasing the global supply of vaccines are the complex manufacturing processes and the time it takes to build new factories, the company said in a statement shared with CNN Business. “Patents are not the limiting factor,” he said.
How much have companies made so far?
BioNTech made a net profit of 1.1 billion euros (US $ 1.3 billion) in the first quarter of the year, largely due to its share of the sales of the Covid-19 vaccine. During the same period last year, the company recorded a loss of € 53.4 million (US$ 75,9 millones).
Moderna’s COVID-19 vaccine sales reached $ 1.7 billion in the first three months of this year. It was the company’s first profitable quarter, as reported in early May. Goldman Sachs expects Moderna to see $ 13.2 billion in vaccine revenue in 2021. The company received billions of dollars in US government funding for drug development.
Read also: Dogecoin Achieves 20% Profit: Now Worth Over $ 53 Billion and Declares Doge Day
CanSino Biologics and Moderna did not respond to a request for comment.. In a statement last month, Bancel said Moderna is willing to license its intellectual property to other companies “for the post-pandemic period.”
AstraZeneca, which developed a vaccine with researchers at the University of Oxford, agreed to provide doses at cost until at least July 2021, and in perpetuity for low- and middle-income countries. Johnson & Johnson has also said it will provide its vaccine non-profit while the world continues to suffer from the pandemic.
CNN’s Chris Isidore and Naomi Thomas contributed to this report.
– .
